Article

Some UTIs may be caused by foodborne illness

Some drug-resistant Escherichia coli strains causing urinary tract infections may have an animal origin, according to an article in Clinical Infectious Diseases (2005; 40:251-7).

Related Videos
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
1 expert in this video
Using Ultrasensitive PSA Assays in Routine Practice
1 expert in this video
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Related Content
Neal D. Shore, MD, FACS
June 4th 2025

How immunotherapy and trials are redefining the treatment of bladder cancer

Urology Times staff
The Clinical Forum underscored the importance of clinical trials and multidisciplinary collaboration in advancing bladder cancer care.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
June 4th 2025

ARANOTE: Darolutamide improves HRQoL in mHSPC

Benjamin P. Saylor
Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
FDA approves darolutamide in metastatic castration-sensitive prostate cancer
June 3rd 2025

FDA approves darolutamide in metastatic castration-sensitive prostate cancer

Hannah Clarke
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
Enzalutamide plus ADT continues to show durable survival benefit in mHSPC at 5 years
June 3rd 2025

Enzalutamide plus ADT continues to show durable survival benefit in mHSPC at 5 years

Hannah Clarke
According to the authors, these data continue to support enzalutamide plus ADT as a standard-of-care for patients with mHSPC.
© 2025 MJH Life Sciences

All rights reserved.